The Research On Efficacy Of Chronic Obstructive Pulmonary Disease With Deficiency Of Both Lung And Spleen In Stable Condition With The Management Of Qiangji Jianli Oral Liquid

Objective:The aim of the study was to assess the clinical effect of Qiangji Jianli Oral Liquid(QJOL) on COPD patients with deficiency of both lung and spleen in stable condition.The other aim of the study was to evaluate the effect of Qiangji Jianli Oral Liquid on chronic obstructive pulmonary disease(COPD) rat models and the expression and distribution of transforming growth factor-β₁, (TGF-β₁) in bronchus and the lung tissue of COPD.Method:1.60 patients conforming to the condition were randomly assigned to the treating group or to the control group .The treating group was treated with QJOL combined with slow-release aminophylline, and the control group was treated only with slow-release aminophylline. The course was three months. The clinical symptoms and sign, spirometry of two groups were observed and compared.2.40 Wistar rats were randomly divided into four groups, including the normal group, the modeled group, the high herb group and the low herb group. The COPD rat model was established by intratracheal instillation of lipopolysaccharide twice with simaltaneous daily exposure to cigarette smoking and then the rats were treated with gastric infusion of senna leaf steep. When the therapy finished, we observed the lung pathology change of every groups with HE stain and compared TGF-β₁ protein expression in bronchus and lung tissue with immunohistochemistry.Result: 1. The total effective rate of the therapeutic group and the control group were 96.43% and 67.86% respectively, The clinical symptoms and sign of the treating group have significant difference (p＜0.05) after three-month comparing with the pre-treatment which showed the management of the treating group could improve the clinical symptoms and sign of COPD patients in stable condition. Compared with the pre-treatment, the control group have significant difference (p＜0.05)in some symptoms and signs, such as cough, sputum, breathlessness, gasp, rhonchus, wet rale. It showed that the therapy of control group also could improve some of the clinical symptoms and sign of COPD patients. The clinical symptoms and sign of the treating group have significant difference (p＜0.05)after three-month comparing with the control group except for gasp and rhonchus.2. Spirometry: After the treatment, melioration of FEV₁, FEV₁% and FEV₁/FVC in both groups have significant difference, but there is no significant difference in FVC. The melioration of spirometry has no significant difference between the two groups after three-month. This show that the therapy of the trial group is the same as the one of the control group.3. The changes in histopathology in the animal model were similar to those in COPD patients. The high dose of QJOL lessen apparently than model group about the changes in histopathology. TGF-β₁ protein expression of model group is stronger than normal control group's. TGF-β1 protein expression of high dose of QJOL is apparente weaker than model group's. But we need the further research about the diffrence between the low dose of QJOL group and the model group and the diffrence between the two doses of group.Conclusion :1. The results indicate that the treatment of QJOL combined with slow-release aminophylline can improve clinical symptoms and sign. But in the improvement of the Spirometry ,the two groups have no significant difference.2. The QJOL can improve the COPD rat models and decrease TGF-β₁ protein expression of bronchus and lung tissue. TGF-β₁ takes part in the space of airway remodeling. Therefore, we can conclude that QJOL may slow the space of airway remodeling...